Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
130.67
-0.78 (-0.60%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Inhibrx Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -140.06 | 1,688 | -241.36 | -115.33 | - | |
| Depreciation & Amortization | 2.48 | 2.29 | 1.19 | 1.23 | - | |
| Other Amortization | 2.44 | 2.07 | 4.9 | - | - | |
| Loss (Gain) From Sale of Assets | 0.01 | 0.01 | 0 | 0.02 | - | |
| Loss (Gain) on Equity Investments | - | - | 1.63 | - | - | |
| Stock-Based Compensation | 11.14 | 58.52 | 24.85 | 17.79 | - | |
| Other Operating Activities | 1.8 | -1,997 | 0.13 | 1.62 | - | |
| Change in Accounts Receivable | 0.2 | -0.19 | -0.54 | 0.13 | - | |
| Change in Accounts Payable | -3.3 | 17.9 | 2.11 | -0.38 | - | |
| Change in Unearned Revenue | - | - | -0.17 | -1.1 | - | |
| Change in Other Net Operating Assets | -4.51 | 34.33 | 13.94 | 5.21 | - | |
| Operating Cash Flow | -129.79 | -194.41 | -193.31 | -90.81 | - | |
| Capital Expenditures | -0.03 | -2.6 | -4.59 | -0.69 | - | |
| Sale of Property, Plant & Equipment | 0 | - | - | - | - | |
| Investing Cash Flow | -0.03 | -2.6 | -4.59 | -0.69 | - | |
| Long-Term Debt Issued | 99.97 | - | - | - | - | |
| Net Debt Issued (Repaid) | 99.97 | - | - | - | - | |
| Issuance of Common Stock | 1.61 | 71.68 | 202.32 | - | - | |
| Other Financing Activities | -0.13 | - | -0.36 | 91.5 | - | |
| Financing Cash Flow | 101.45 | 71.68 | 201.96 | 91.5 | - | |
| Net Cash Flow | -28.38 | -125.33 | 4.06 | - | - | |
| Free Cash Flow | -129.83 | -197.01 | -197.9 | -91.5 | - | |
| Free Cash Flow Margin | -9986.54% | -98503.00% | -10994.56% | -6957.95% | - | |
| Free Cash Flow Per Share | -8.38 | -13.15 | -16.80 | -2.28 | - | |
| Cash Interest Paid | 8.9 | 11.51 | 26.72 | - | - | |
| Cash Income Tax Paid | 0 | 0 | 0 | 0 | - | |
| Levered Free Cash Flow | -84.46 | -92.57 | -106.38 | -55.74 | - | |
| Unlevered Free Cash Flow | -79.27 | -86.21 | -91.38 | -55.74 | - | |
| Change in Working Capital | -7.61 | 52.05 | 15.35 | 3.86 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.